Veloxis Pharmaceuticals AS – Strategy, SWOT and Corporate Finance Report

Veloxis Pharmaceuticals AS – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Scope

Detailed information on Veloxis Pharmaceuticals AS required for business and competitor intelligence needs

A study of the major internal and external factors affecting Veloxis Pharmaceuticals AS in the form of a SWOT analysis

An in-depth view of the business model of Veloxis Pharmaceuticals AS including a breakdown and examination of key business segments

News about Veloxis Pharmaceuticals AS, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Veloxis Pharmaceuticals AS and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Veloxis Pharmaceuticals AS as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Veloxis Pharmaceuticals ASs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Roche a/s

Metkinen Oy

Quantum Genomics SA

Sanofi-aventis Canada Inc

Novartis Pharmaceuticals UK Ltd

Genzyme Corp

Astellas Pharma A/S

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Veloxis Pharmaceuticals AS - Key Facts

Veloxis Pharmaceuticals AS - Key Employees

Veloxis Pharmaceuticals AS - Key Employee Biographies

Veloxis Pharmaceuticals AS - Major Products and Services

Veloxis Pharmaceuticals AS - History

Veloxis Pharmaceuticals AS - Company Statement

Veloxis Pharmaceuticals AS - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Veloxis Pharmaceuticals AS - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Rest of the world (RoW)

Performance

Geographical Segment: United States

Performance

Veloxis Pharmaceuticals AS - Corporate Strategy

Veloxis Pharmaceuticals AS - SWOT Analysis

SWOT Analysis - Overview

Veloxis Pharmaceuticals AS - Strengths

Veloxis Pharmaceuticals AS - Weaknesses

Veloxis Pharmaceuticals AS - Opportunities

Veloxis Pharmaceuticals AS - Threats

Veloxis Pharmaceuticals AS - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Section 5 Company’s Recent Developments

Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance

May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Nov 14, 2018: Veloxis Pharmaceuticals announces financial results for the first nine months of 2018

Oct 31, 2018: Ira Duarte promoted to chief financial officer of Veloxis Pharmaceuticals

Sep 24, 2018: Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals

Aug 13, 2018: Veloxis Pharmaceuticals announces financial results for the first six months of 2018

May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Veloxis Pharmaceuticals AS, Key Facts

Veloxis Pharmaceuticals AS, Key Employees

Veloxis Pharmaceuticals AS, Key Employee Biographies

Veloxis Pharmaceuticals AS, Major Products and Services

Veloxis Pharmaceuticals AS, History

Veloxis Pharmaceuticals AS, Subsidiaries

Veloxis Pharmaceuticals AS, Key Competitors

Veloxis Pharmaceuticals AS, Ratios based on current share price

Veloxis Pharmaceuticals AS, Annual Ratios

Veloxis Pharmaceuticals AS, Annual Ratios (Cont…1)

Veloxis Pharmaceuticals AS, Interim Ratios

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Veloxis Pharmaceuticals AS, Performance Chart (2014 – 2018)

Veloxis Pharmaceuticals AS, Ratio Charts

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports